GlassScriptPhysician profile
Aimee Renee Cockerham
NPI 1669086096
$5,185.07
in general payments reported to CMS, 2019-2025
25 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $1,985 · 2023: $425 · 2024: $258 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,217.14 | 2021-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $1,207.39 | 2021-2025 | |
| Janssen Biotech, INC. | $397.47 | 2021-2025 | Tremfya, Stelara, Remicade |
| Intercept Pharmaceuticals, INC. | $281.48 | 2021-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $280.04 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.93 | 2021-2025 | Xifaxan |
| Celgene Corporation | $230.51 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $218.42 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $205.45 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $108.24 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $97.20 | 2022 | |
| Qol Medical, LLC | $92.55 | 2025 | Sucraid |
| Lilly USA, LLC | $85.83 | 2023-2025 | Omvoh |
| Novo Nordisk INC | $83.00 | 2021 | |
| Madrigal Pharmaceuticals | $81.52 | 2025 | Rezdiffra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68.34 | 2022 | |
| Celltrion USA INC. | $63.16 | 2025 | Vegzelma |
| Pfizer INC. | $47.36 | 2022-2025 | |
| Braintree Laboratories, INC. | $33.91 | 2021-2022 | |
| Redhill Biopharma INC. | $31.06 | 2021 | |
| Aimmune Therapeutics, INC. | $29.92 | 2025 | Zenpep |
| Mirum Pharmaceuticals, INC. | $16.52 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.23 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.53 | 2022 | |
| Evoke Pharma, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Cockerham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.